---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-101974"
form_type: "8-K"
ticker: "SNDX"
cik: "0001395937"
company_name: "Syndax Pharmaceuticals Inc"
filed_at: "2025-08-04T23:59:59+00:00"
generated_at: "2026-05-17T21:24:19.209340+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Syndax Q2 Revuforj revenue $28.6M (+43% QoQ); sNDA for mNPM1 AML with Priority Review

## Summary
- Revuforj net revenue $28.6M in Q2 2025, 43% increase over Q1 2025.
- Niktimvo net revenue $36.2M (Incyte-reported); Syndax collaboration revenue $9.4M.
- sNDA for Revuforj in R/R mNPM1 AML granted Priority Review; PDUFA Oct 25, 2025.
- Cash, cash equivalents and investments $517.9M; expect funding to profitability.
- Net loss $71.8M ($0.83/sh) vs $68.1M ($0.80/sh) year ago.

## SEC filing metadata
- accession: 0000950170-25-101974
- form_type: 8-K
- ticker: SNDX
- cik: 0001395937
- company_name: Syndax Pharmaceuticals Inc
- filed_at: 2025-08-04T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1395937/000095017025101974/0000950170-25-101974-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1395937/000095017025101974/sndx-20250804.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-101974
- JSON: https://secwatch.observer/filing/0000950170-25-101974.json
- Plain text: https://secwatch.observer/filing/0000950170-25-101974.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.